Innoviva has a 5 year average dividend yield of 2.28%
Innoviva, Inc. (NASDAQ:INVA) witnessed a decline in the market cap on Thursday as its shares dropped 0.37% or 0.045 points. After the session commenced at $12.04, the stock reached the higher end at $12.2 while it hit a low of $11.83. With the volume soaring to 711,912 shares, the last trade was called at $12.005. The company has a 52-week high of $14.15. The company has a market cap of $1,305 million and there are 108,731,402 shares in outstanding. The 52-week low of the share price is $8.67. Shares of Innoviva, Inc. rose by 8.15% in the last five trading days and 10.54% for the last 4 weeks. Innoviva, Inc. is up 7.86% in the last 3-month period. Year-to-Date the stock performance stands at 12.2%.
Currently the company Insiders own 1.6% of Innoviva, Inc. shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -1.41% . Institutional Investors own 77.62% of Innoviva, Inc. shares. During last six month period, the net percent change held by insiders has seen a change of -1.41%. Company has reported several Insider transactions to the SEC, on Nov 22, 2016, Eric Desparbes (SVP and CFO) sold 1,800 shares at 10.89 per share price.On Nov 22, 2016, Theodore L Jr Witek (Sr. VP & Chief Scientific Off.) sold 3,700 shares at 10.84 per share price.On May 20, 2016, James L Tyree (director) sold 813 shares at 10.47 per share price.
Innoviva Inc Last issued its quarterly earnings results on Feb 9, 2017. The company reported $0.22 EPS for the quarter. Analyst had a consensus estimate of $0.22. The company had revenue of $43.61 million for the quarter, compared to analysts expectations of $41.79 million. The companys revenue was up 90.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.04 EPS.
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The companys portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.